| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NT5E |
| Uniprot No | P21589 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-549aa |
| 氨基酸序列 | WELTILHTNDVHSRLEQTSEDSSKCVNASRCMGGVARLFTKVQQIRRAEPNVLLLDAGDQYQGTIWFTVYKGAEVAHFMNALRYDAMALGNHEFDNGVEGLIEPLLKEAKFPILSANIKAKGPLASQISGLYLPYKVLPVGDEVVGIVGYTSKETPFLSNPGTNLVFEDEITALQPEVDKLKTLNVNKIIALGHSGFEMDKLIAQKVRGVDVVVGGHSNTFLYTGNPPSKEVPAGKYPFIVTSDDGRKVPVVQAYAFGKYLGYLKIEFDERGNVISSHGNPILLNSSIPEDPSIKADINKWRIKLDNYSTQELGKTIVYLDGSSQSCRFRECNMGNLICDAMINNNLRHTDEMFWNHVSMCILNGGGIRSPIDERNNGTITWENLAAVLPFGGTFDLVQLKGSTLKKAFEHSVHRYGQSTGEFLQVGGIHVVYDLSRKPGDRVVKLDVLCTKCRVPSYDPLKMDEVYKVILPNFLANGGDGFQMIKDELLRHDSGDQDINVVSTYISKMKVIYPAVEGRIKFS |
| 预测分子量 | 60.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NT5E(CD73)重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *CD73 in Cancer Development and Targeted Therapy*
**作者**: Antonioli, L. 等人 (2016)
**摘要**: 该综述探讨了CD73在肿瘤微环境中的作用，指出其通过生成腺苷抑制抗肿瘤免疫反应。研究总结了重组CD73蛋白在实验中的应用，包括验证其酶活性和作为治疗靶点的潜力，并讨论了靶向CD73的抗体和抑制剂开发进展。
---
2. **文献名称**: *Structural Basis of Nucleotide Conversion by CD73*
**作者**: Zhang, B. 等人 (2020)
**摘要**: 通过X射线晶体学解析了重组人源CD73蛋白的三维结构，揭示了其催化AMP转化为腺苷的分子机制。研究为设计特异性抑制剂提供了结构基础，并验证了重组蛋白的酶活性在体外实验中的可靠性。
---
3. **文献名称**: *CD73-Generated Adenosine Limits Inflammation and Tissue Damage in Experimental Colitis*
**作者**: Savio, L.E.B. 等人 (2018)
**摘要**: 研究利用重组CD73蛋白处理小鼠结肠炎模型，发现其通过增加腺苷水平减轻炎症和组织损伤。结果支持CD73在炎症性疾病中的保护作用，并提示重组蛋白可能作为治疗工具用于调节免疫反应。
---
这些文献涵盖了NT5E/CD73的病理机制、结构功能及治疗应用方向，均涉及重组蛋白的实验验证或应用。如需更多文献，可进一步限定研究领域或时间范围。
NT5E (Ecto-5'-nucleotidase), also known as CD73. is a membrane-bound glycoprotein enzyme encoded by the NT5E gene. It plays a critical role in purinergic signaling by catalyzing the hydrolysis of extracellular adenosine monophosphate (AMP) to adenosine, a potent signaling molecule. This enzymatic activity links NT5E to the regulation of immune responses, inflammation, and tissue homeostasis. Adenosine binds to specific receptors (A1. A2A, A2B, A3) on immune and stromal cells, modulating pathways that can suppress immune activation—a mechanism exploited by tumors to evade immune surveillance.
Recombinant NT5E protein is produced through genetic engineering, typically using mammalian expression systems to ensure proper post-translational modifications. The recombinant form often retains the extracellular domain (residues 1-549) while omitting the transmembrane and cytoplasmic regions, creating a soluble protein for experimental applications. It is widely used in vitro to study adenosine-mediated processes, including tumor immune evasion, angiogenesis, and fibrosis. Researchers utilize recombinant NT5E to investigate its interaction with therapeutic antibodies or inhibitors targeting its enzymatic active site.
Clinically, NT5E overexpression correlates with poor prognosis in cancers like melanoma, glioblastoma, and breast cancer, making it a potential biomarker and therapeutic target. Its role in immune suppression has spurred development of anti-CD73 antibodies for combination therapies with immune checkpoint inhibitors. Beyond oncology, NT5E dysfunction is implicated in cardiovascular diseases and autoimmune disorders. Recombinant protein studies continue to clarify its structural nuances, including dimerization requirements and zinc-binding catalytic sites, driving innovations in precision medicine approaches.
×
